Study of outcomes in genetic Wilson disease patients
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at the health features and long-term outcomes in people with Wilson disease who have a genetic diagnosis. It may help doctors understand what to expect over time for different patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Wilson disease confirmed by genetic testing
- You are willing to be followed for the study period
- You do not plan to deny or refuse follow-up visits or contact
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who already have a genetic diagnosis of Wilson disease. It looks at whether specific lab tests and a physical eye finding can help confirm and support the diagnosis.
This early-stage trial tests LY-M003, a new gene therapy treatment for Wilson's disease—a rare genetic condition where copper builds up in the body. The study aims to see if this injection is safe and whether it can help patients who are already on standard copper-lowering medicines.
This study tests an injection called LY-M003 for people with Wilson disease who have already been treated with standard medicines. The goal is to see if it is safe and works for them.
This study follows people who have the genetic cause of Wilson disease, including people who feel well and family members. Researchers want to better understand Wilson disease and what to watch for over time.
This study follows people who already have Wilson disease to understand how the condition changes over time. It may help researchers better predict future symptoms and improve care.
This study looks at how Wilson's disease affects the kidneys. It aims to better understand kidney problems in people with Wilson's disease, which could help improve care.
Hear when a new Clinical Features and Outcome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.